Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population

Genetics in Medicine

Volumn 11, Issue 11, 2009, Pages 783-789

  Bellcross, Cecelia A ^a,f   Lemke, Amy A ^b   Pape, Laura S ^c   Tess, Angela L ^d   Meisner, Lorraine T ^e  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Froedtert and Community Health   (United States)

^d St Vincent's Hospital   (United States)

^e Cell Line Genetics   (United States)

^f NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Breast cancer; Cancer genetics; Genetic screening; Hereditary neoplastic syndromes; Ovarian cancer

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER SCREENING; FEMALE; GENETIC COUNSELING; GENETIC MODEL; GENETIC RISK; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE; OVARY CANCER; PATIENT REFERRAL; PEDIGREE ANALYSIS; PREDICTION; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MAMMOGRAPHY; OVARIAN NEOPLASMS; QUESTIONNAIRES;

EID: 73849147443     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181b9b04a     Document Type: Article

References (52)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389-1399.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-2529.
3. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-1308.
4. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706.
5. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104:2807-2816.
6. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 1994; 343:692-695.
7. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-1130.
8. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-1333.
9. Marroni F, Aretini P, D'Andrea E, et al. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. Eur J Hum Genet 2004;12:899-906.
10. Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006;25:5825-5831.
11. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 2004;22:1055-1062. (Pubitemid 41095038)
12. Rebbeck TR, Kauff ND, Domcheck SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-87.
13. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-1615.
14. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-7496. (Pubitemid 46291812)
15. Kriege M, Brekelmans CT, Boetes C, et al; Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-437.
16. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006;7:223-229.
17. Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer 2002;94: 305-313.
18. Sweet KM, Bradley TL, Westman JA. Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol 2002;20:528-537.
19. Hughes KS, Roche C, Campbell CT, et al. Prevalence of family history of breast and ovarian cancer in a single primary care practice using a self-administered questionnaire. Breast J 2003;9:19-25.
20. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676.
21. White DB, Bonham VL, Jenkins J, Stevens N, McBride CM. Too many referrals of low-risk women for BRCA1/2 genetic services by family physicians. Cancer Epidemiol Biomarkers Prev 2008;17:2980-2986.
22. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-1415.
23. Shattuck-Eidens D, Oliphant A, McClure M, et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997;278:1242-1250.
24. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-1130.
25. Berry DA, Iversen ES Jr, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701-2712.
26. Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004;91: 1580-1590.
27. Evans DG, Eccles DM, Rahman N, et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004;41:474-480.
28. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors. J Genet Couns 2004;13:83-114.
29. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the national society of genetic counselors. J Genet Couns 2007;16:241-260.
30. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-361.
31. Hampel H, Sweet K, Westman JA, Offit K, Eng C. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004;41:81-91.
32. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Genetic/familial high-risk assessment: breast and ovarian. V.I. 2008. Available at: http://www.nccn.org/professionals/physician-gls/PDF/ genetics-screening.pdf. Accessed December 1, 2008.
33. Antoniou AC, Cunningham AP, Peto JP, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008;98:1457-1466.
34. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158.
35. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490.
36. Myriad Genetic Laboratories, Inc. BRCA Mutation Prevalence Tables. Available at http://www.myriadtests.com/provider/brca-mutation-prevalence.htm. Accessed April, 2009.
37. Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 2000;58:299-308.
38. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006;2:257-274.
39. Barcenas CH, Hosain GM, Arun B, et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 2006;24:354-360.
40. James PA, Doherty R, Harris M, et al. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 2006;24:707-715.
41. Bodmer D, Ligtenberg MJ, van der Hout AH, et al. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models. Br J Cancer 2006;95:757-762.
42. Marroni F, Aretini P, D'Andrea E, et al. Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet 2004;41:278-285.
43. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-1736.
44. Burke W, Culver JO, Bowen D, et al. Genetic counseling for women with an intermediate family history of breast cancer. Am J Med Genet 2000;90:361-368.
45. Saslow D, Boetes C, Burke W, et al; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
46. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
47. Hoskins KF, Zwaagstra A, Ranz M. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer 2006;107:1769-1776.
48. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-2335. (Pubitemid 41115389)
49. Steinmann D, Bremer M, Rades D, et al. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 2001; 85:850-858. (Pubitemid 33010552)
50. Ready KJ, Vogel KJ, Atchley DP, et al. Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 2009;115:725-730.
51. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292:1480-1489.
52. Mouchawar J, Hesley-Alford S, Laurion S, et al. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: a naturally occurring experiment. Genet Med 2005;7:191-197. (Pubitemid 40478156)